History of Immunoglobulin Replacement

Immunology and Allergy Clinics of North America

Volumn 28, Issue 4, 2008, Pages 737-764

  Eibl, Martha M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antibody deficiency; Immune modulation; Immunoglobulin; IVIg treatment; Primary immunodeficiency

Indexed keywords

2 DIETHYLAMINOETHANOL; ACETYLSALICYLIC ACID; ALCOHOL; ANTIBODY; CARIMUNE; CYTOKINE; DIETHYLAMINOETHYL SEPHADEX; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; MACROGOL; MEASLES VACCINE; MONOCLONAL ANTIBODY; PEPSIN A; PLASMA PROTEIN; PLASMIN; PROPIOLACTONE; PROSTAGLANDIN; TETANUS TOXIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; AGAMMAGLOBULINEMIA; ALLERGY; ANAPHYLAXIS; ANXIETY; AUTOIMMUNE DISEASE; BENIGN CHILDHOOD EPILEPSY; BLOOD PRESSURE; BONE MARROW TRANSPLANTATION; BULLOUS PEMPHIGOID; CHEST TIGHTNESS; CHICKENPOX; CHILDHOOD DISEASE; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATOMYOSITIS; DIABETES MELLITUS; DIPHTHERIA; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; EATON LAMBERT SYNDROME; ENDOCRINE OPHTHALMOPATHY; ENTEROCOLITIS; EVIDENCE BASED MEDICINE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEART PALPITATION; HEPATITIS A; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; INFECTION PREVENTION; INFLAMMATION; LOADING DRUG DOSE; LOW BACK PAIN; MEASLES; MONOTHERAPY; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUMPS; MYASTHENIA GRAVIS; NAUSEA; NEOPLASM; NEPHROTOXICITY; NERVOUSNESS; NEWBORN SEPSIS; NONHUMAN; OFF LABEL DRUG USE; PERTUSSIS; PLASMA; PNEUMONIA; POLIOMYELITIS; POLYMYOSITIS; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SERUM; SHOCK; SIDE EFFECT; SINUSITIS; STEVENS JOHNSON SYNDROME; STIFF MAN SYNDROME; SUBSTITUTION THERAPY; TACHYCARDIA; TETANUS; THROMBOCYTOPENIC PURPURA; THROMBOEMBOLISM; THYROID DISEASE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VACCINATION; VIRUS TRANSMISSION; VOMITING; WHEEZING;

ANIMALS; ANTIBODIES, MONOCLONAL; CONSENSUS DEVELOPMENT CONFERENCES, NIH AS TOPIC; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 53649102120     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2008.06.004     Document Type: Review

References (217)

1. von Behring E.A., and Kitasato S. Über das zustandekommen der diphtherie-immunität und der tetanus-immunität bei tieren. Dtsch Med Wochenschr 16 (1890) 1113-1114
2. Ehrlich P. Experimentelle untersuchungen über immunität. I. Über Ricin. II. Über Abrin. Dtsch Med Wochenschr 17 (1891) 976-979 1218-9
3. Wolff-Eisner A. Handbuch der serumtherapie und experimentellen therapie: ein handbuch für klinik und praxis (1910), J.F. Lehmanns Verlag, München
4. Verhandlungen der Berliner Medizinischen Gesellschaft 1894.
5. Calmette A. Die gifte, die gifttiere und die serumtherapie gegen die tierischen gifte (1907), Masson, Paris
6. Flexner S. Experimental cerebro-spinal meningitis in monkeys. J Exp Med 9 (1907) 142-167
7. Flexner S. Concerning a serum therapy for experimental infections with Diplococcus intracellularis. J Exp Med 9 (1907) 168-185
8. Eibl M.M., and Wedgwood R.J. Intravenous immunglobulin: a review. Immunodefic Rev 1 Suppl (1989) 1-42
9. Cenci F. Alcune esperienze di sieroimmunizzaziuone e sieroterapie nel norbillo. Rivista di Clinica e Pediatrica 5 (1907) 1017-1025
10. McKhann C.F., and Chu F.T. Use of placental extract in prevention and modification of measles. Am J Dis Child 45 (1933) 475-479
11. Gibson R.B. The concentration of antitoxin for therapeutic use. J Biol Chem 1 (1906) 161-170
12. Karelitz S. Prophylaxis against measles with the globulin fraction of immune adult serum. Am J Dis Child 55 (1938) 768-775
13. Tiselius A., and Kabat E.A. Electrophoresis of immune serum. Science 87 (1938) 416-417
14. Cohn E.J. Blood proteins and their therapeutic value. Science 101 (1945) 51-56
15. Cohn E.J., Luetscher Jr. J.A., Oncley J.L., et al. Preparation and properties of serum and plasma proteins. J Am Chem Soc 62 (1940) 3396-3400
16. Cohn E.J. The history of plasma fractionation. In: Merler E. (Ed). Advances in military medicine vol. 1 (1948), Little, Brown and Company, Boston p. 364-443
17. Janeway C.A. The development of clinical uses of immunoglobulins: a review. Immunoglobulins (1970), National Academy of Science, Washington, DC 3-14
18. Stokes J., Maris E.P., and Gellis S.S. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XI. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prophylaxis and treatment of measles. J Clin Invest 23 (1944) 531-540
19. Stokes J., and Neefe J.R. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 127 (1945) 144-145
20. Nation N.S., Pierce N.F., Adler S.J., et al. Tetanus; the use of human hyperimmune globulin in treatment. Calif Med 98 (1963) 305-307
21. Pollack W., Gorman J.G., Freda V.J., et al. Results of clinical trials of RhoGAM in women. Transfusion 8 3 (1968) 151-153
22. Zuckermann A.J. Prophylaxis of hepatitis type B: immunoglobulins and vaccines. Clin Gastroenterol 9 1 (1980) 65-83
23. Goebel U., Schwamborn D., Moeller B., et al. Intravenous hyperimmunoglobulin to prevent varicella-zoster infection. Pediatr Infect Dis 6 23 (1987) 224
24. Welliver R.C. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection. Semin Perinatol 22 1 (1998) 87-95
25. Storch G.A. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics 102 (1998) 648-651
26. Centers for Diseases Control and Prevention (CDC). Recommendations of the Immunization Practices Advisory Committee (ACIP) Varicella-Zoster Immune Globulin for the prevention of chickenpox. Morbidity and Mortality Weekly Report (MMWR) 33 7 (1984) 84-90 95-100
27. Bruton O.C. Agammaglobulinemia. Pediatrics 9 (1952) 722-727
28. Good R.A., and Varco R.L. A clinical and experimental study of agammaglobulinemia. Lancet 75 6 (1955) 245-271
29. Gitlin D., and Janeway D.C. Agammaglobulinemia: congenital, acquired and transient forms. Prog Hematol 1 (1956) 318-329
30. Barandun S. Die gammaglobulin-therapie: chemische, immunologische und klinische grundlagen. Bibl Haematol 17 (1964) 1-138
31. Stiehm E.R. Immunodeficieny disorders: general considerations. In: Stiehm E.R., and Fulginiti V.A. (Eds). Immunologic disorders in infants and children (1973), WB Saunders, Philadelphia 145-167
32. Hitzig W.H., and Muntener U. Conventional immunoglobulin therapy. In: Gerdsma D. (Ed). Immunodeficiency in man and animals (1975), Sinauer Associates, Sunderland (MA) 339-342
33. Domz C.A., and Dickson D.R. The agammaglobulinemics: relation and implications. Am J Med 23 (1957) 917-927
34. Janeway C.A., and Rosen F.S. The gamma globulins. IV. Therapeutic uses of gamma globulin. N Engl J Med 275 (1966) 826-831
35. Report of a WHO Scientific Group. The use of human immunoglobulin. Technical Report Series (1966) 327
36. Fudenberg H.H., Good R.A., Goodman H.C., et al. Primary immunodeficiencies: report of a World Health Organization committee. Pediatrics 47 (1971) 927-946
37. Cooper M.D., Faulk W.P., Fudenberg H.H., et al. Classification of primary immunodeficiencies. N Engl J Med 288 (1973) 966-967
38. Report of a WHO Scientific Group. Immunodeficiency: technical report series. Document no. 630 (1978), World Health Organization, Geneva (Switzerland) p. 3-80
39. Abernathy R.S., Strem E.L., and Good K.A. Chronic asthma in childhood: double-blind controlled study of treatment with gamma-globulin. Pediatrics 21 6 (1958) 980-993
40. MRC Working Party on Hypogammaglobulinaemia. Hypogammaglobulinaemia in the United Kingdom (1971), Her Majestýs Stationery Office, London
41. Tabor E., and Gerety R.J. Transmission of hepatitis B by immuno serum globulin. Lancet 2 8155 (1979) 1293
42. John T.J., Ninan G.T., Rajagopalan H.S., et al. Epidemic hepatitis B caused by commercial human immunoglobulin. Lancet 1 8125 (1979) 1074
43. da Silva L.C., Sette H., Antonacio F., et al. Commercial gammaglobulin (CGG) as a possible vehicle of transmission of HbsAG in familial clustering. Rev Inst Med Trop Sao Paulo 19 (1977) 352-354
44. Petrilli F.L., Crovari P., and De Flora S. Hepatitis B in subjects treated with a drug containing immunoglubulins. J Infect Dis 135 (1977) 252-258
45. Morell A., Schnoz M., and Barandun S. Build-up and maintenance of IgG serum concentrations with intravenous immunoglobulin in patients with primary humoral immunodeficiency. Vox Sang 43 (1982) 212-219
46. Smith G.N., Griffiths B., Mollison D., et al. Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1 7762 (1972) 1208-1212
47. Haeney M.R., Carter G.F., Yeoman W.B., et al. Long-term parenteral exposure to mercury in patients with hypogammaglobulinemia. BMJ 2 (1979) 12-14
48. Matheson D.S., Clarkson T.W., and Gelfand E.W. Mercury toxicity (acrodynia) induced by long-term injection of gammaglobulin. J Pediatr 97 (1980) 153-155
49. Barandun S., Kistler P., Jeunet F., et al. Intravenous administration of human gammaglobulin. Vox Sang 7 (1962) 157-174
50. Ammann A.J., Ashman R.F., Buckley R.H., et al. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 22 (1982) 60-67
51. Lederman H.M., and Winkelstein J.A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 64 (1985) 145-156
52. Quartier P., Debre M., De Blic J., et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 134 (1999) 589-596
53. Cunningham-Rundles C., Siegal F.P., Smithwick E.M., et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 101 (1984) 435-439
54. Nolte M.T., Pirofsky B., Gerritz G.A., et al. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 36 (1979) 237-243
55. Roifman C.M., Lederman H.M., Lavi S., et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med 79 (1985) 171-174
56. Skvaril F., Probst M., Steinbuch A., et al. Distribution of IgG subclasses in commercial and some experimental γ-globulin preparations. Vox Sang 32 (1977) 335-338
57. Römer J., Morgenthaler J.J., Scherz R., et al. Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang 42 (1982) 62-73
58. Morell A., Schürch B., Ryser D., et al. In vivo behaviour of gamma globulin preparations. Vox Sang 38 (1980) 272-283
59. Ochs H.D. Intravenous immunoglobulin therapy of patients with primary immunodeficiency syndromes: efficacy and safety of a new immune globulin preparation. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), Washington DC: US Department of Health and Human Services 9-14
60. Pirofsky B., Anderson C.J., and Bardana E.J. Therapeutic and detrimental effects of intravenous immunoglobulin therapy. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), US Department of Health and Human Services, Washington DC 15-22
61. Barandun S., Morell A., and Skvaril F. Clinical experiences with immunoglobulin for intravenous use. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), US Department of Health and Human Services, Washington DC 31-35
62. Mondorf A.W., and Duswald K.H. Intravenous immunoglobulin in high-risk patients: efficacy and tolerance of long-term administration. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), US Department of Health and Human Services, Washington DC 37-40
63. Alving B.M., and Finlayson J.S. Preface. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), US Department of Health and Human Services, Washington DC 9-14
64. Overview of potential uses for immunoglobulin preparations, possible etiologies of adverse reactions and ideal characteristics of intravenous preparations. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations, proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), Washington DC: US Department of Health and Human Services 229-233
65. Eibl M. Treatment of defects of humoral immunity. Birth Defects Orig Artic Ser 19 3 (1983) 193-200
66. Kjellman H. Adverse reactions to human immune serum globulin in Sweden (1969-1978). In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), US Department of Health and Human Services, Washington DC 143-150
67. Hanson L.A., Björkander J., Ljunggren C., et al. Problems with use of immunoglobulins in treatment of immunodeficiency patients. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), US Department of Health and Human Services, Washington DC 150-159
68. Cassidy J.T., Stein L.D., and Reynolds R.T. Intravenous immune globulin: five-year clinical experience with efficacy and adverse reactions in immunodeficiency. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), US Department of Health and Human Services, Washington DC 161-166
69. Funakoshi S., Suyama T., and Naito R. Use of Intravenous immunoglobulin in Japan. In: Alving B.M., and Finlayson J.S. (Eds). Immunglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), US Department of Health and Human Services, Washington DC 219-225
70. Busse P.J., Razvi S., and Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109 6 (2002) 1001-1004
71. Brunko P. Community requirements relating to drugs derived from human blood and plasma. Ann Pharm Fr 52 2 (1994) 89-98
72. Orange J.S., Hossny E.M., Weiler C.R., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 (2006) S525-S553
73. Barandun S., and Isliker H. Development of immunoglobulin preparations for intravenous use. Vox Sang 51 (1986) 157-160
74. Imbach P., d'Apuzzo V., and Hirt A. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 8232 (1981) 1228-1231
75. Fehr J., Hofmann V., and Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306 (1982) 1254-1258
76. Mori P.G., Mancuso G., del Principe D., et al. Chronic idiopathic thrombocytopenia treated with immunoglobulin. Arch Dis Child 58 (1983) 851-855
77. Carroll R.R., Noyes W.D., Rosse W.H., et al. Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. Am J Med 76 Suppl 3a (1984) 181-186
78. Warrier I., and Lusher J.M. Intravenous gammaglobulin treatment for chronic idiopathic thrombocytopenic purpura in children. Am J Med 76 (1984) 193-198
79. Warrier L.A., and Lusher J.M. Intravenous gammaglobulin (Gamimune) for treatment of chronic idiopathic thrombocytopenic purpura (ITP): a two-year follow-up. Am J Hematol 23 (1986) 323-328
80. Bussel J. Intravenous immune serum globulin in immune thrombocytopenia: clinical results and biochemical evaluation. Vox Sang 49 Suppl 1 (1985) 44-50
81. Vos J.J., van Aken W.G., Engelffriet C.P., et al. Intravenous gammaglobulin therapy in idiopathic thrombocytopenic purpura. Vox Sang 49 (1985) 92-100
82. Abe T., Matsuda J., Kawasugi K., et al. Clinical effect of intravenous immunoglobulin on chronic idiopathic thrombocytopenic purpura. Blut 47 2 (1983) 69-75
83. Becton D.L., Kinney T.R., Chaffee S., et al. High-dose intravenous immunoglobulin for severe platelet alloimmunization. Pediatrics 74 (1984) 1120-1123
84. Hanada T., Saito K., Nagasawa T., et al. Intravenous gammaglobulin therapy for thromboneutropenic neonates of mothers with systemic lupus erythematosus. Eur J Haematol 38 (1987) 400-404
85. Derycke M., Dreyfus M., Ropert J.C., et al. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia. Arch Dis Child 60 (1985) 667-669
86. Berlin G., Selbing A., and Ryden G. Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin. [letter]. Lancet 1 8438 (1985) 1153
87. Drachman D.B., Adams R.N., Josifek L.F., et al. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 307 (1982) 769-775
88. Morel E., Eymard B., Vernet-der-Garabedian B., et al. Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases. Neurology 38 (1988) 138-142
89. Ruhr G., Kusterer K., Schille M., et al. Treatment of Crohńs disease and ulcerative colitis with 7S-immunoglobulin. [letter]. Lancet I (1987) 170
90. Pocecco M., de Campo C., Cantoni L., et al. Effect high dose intravenous IgG in newly diagnosed diabetic children. Helv Paediatr Acta 42 (1987) 289-295
91. Silverstein J., Maclaren N., Riley W., et al. Immunosuppression with azathioprine and prednisone in recent-onset-dependent diabetes mellitus. N Engl J Med 319 (1988) 599-604
92. Antonelli A., Navarranne A., Palla R., et al. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid 4 4 (1994) 399-408
93. Baschieri L., Antonelli A., Nardi S., et al. Intravenous immunoglobulin versus corticosteroid in treatment of Gravés ophthalmopathy. Thyroid 7 4 (1997) 579-585
94. Kahaly G., Pitz S., Müller-Forell W., et al. Randomized trial of intravenous immunoglobulin versus prednisolone in Gravés ophthalmopathy. Clin Exp Immunol 106 2 (1996) 197-202
95. Czernik A., and Bystryn J.C. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 144 5 (2008) 658-661
96. Tovo P.A., Miniero R., Fiandino G., et al. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr 105 4 (1984) 676-677
97. Burdach S.E., Evers K.G., and Geursen R.G. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations. J Pediatr 109 5 (1986) 770-775
98. Basta M., Langlois P.F., Marques M., et al. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 74 1 (1989) 326-333
99. Frank M.M., Basta M., and Fries L.F. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 62 1 Pt 2 (1992) S82-S86
100. Lin R.Y., and Racis S.P. In vivo reduction of circulating Clq binding immune complexes by intravenous gammaglobulin administration. Int Arch Allergy Appl Immunol 79 (1986) 286-290
101. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329 27 (1993) 1993-2000
102. Basta M., and Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94 5 (1994) 1729-1735
103. Bussel J.B. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 37 3 (2000) 261-266
104. Bussel J.B., Graziano J.N., Kimberly R.P., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 77 9 (1991) 1884-1893
105. Becker T., Kuenzlen E., Salama A., et al. Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D). Eur J Pediatr 45 (1986) 166-169
106. Blanchette V., Imbach P., Andrew M., et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344 8924 (1994) 703-707
107. Clarkson S.B., Kimberly R.P., Valinsky J.E., et al. Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med 164 2 (1986) 474-489
108. Clarkson S.B., Bussel J.B., Kimberly R.P., et al. Treatment of refactory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 314 19 (1986) 1236-1239
109. Andemariam B., and Bussel J. New therapies for immune thrombocytopenic purpura. Curr Opin Hematol 14 (2007) 427-431
110. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 10 (2001) 747-755
111. Marchalonis J.J., Kaymaz H., Dedeoglu F., et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci U S A 89 (1992) 3325-3329
112. Kaveri S., Vassilev T., and Hurez V. Antibodies to a conserved region of HLA class I molecules, capable of modulation CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 97 (1996) 865-869
113. Prasad N.K., Papoff G., Zeuner A., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161 (1998) 3781-3790
114. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
115. Dwyer D.S., Bradley R.J., Urquhart C.K., et al. Naturally occurring anti-idiotype antibodies in myasthenia gravis patients. Nature 301 (1983) 611-614
116. Negi V.S., Elluru S., Siberil S., et al. Intravenous immunoglobulin: an update on the clinical use and mechanism of action. J Clin Immunol 27 3 (2007) 233-245
117. Andersson J., Skansén-Saphir U., Sparrelid E., et al. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104 Suppl 1 (1996) 10-20
118. Okitsu-Negishi S., Furusawa S., Kawa Y., et al. Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1. Immunol Res 13 1 (1994) 49-55
119. Sullivan K.M., Kopecky K.J., and Jocom J. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323 11 (1990) 705-712
120. Winston D.J., Ho W.G., Rasmussen L.E., et al. Use of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 28 (2001) 187-196
121. Jordan S.C., Vo A., Bunnapradist S., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76 (2003) 631-636
122. Cordonnier C., Chevret S., Legrand M., et al. Should immunoglobulin therapy be used in allogenic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139 (2003) 8-18
123. Glotz D., Antoine C., Julia P., et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2 (2002) 758-760
124. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 2 (2003) 138-150
125. Munoz C., Carlet J., Fitting C., et al. Dysregulation on in vitro cytokine production by monocytes during sepsis. J Clin Invest 88 (1991) 1747-1754
126. Ertel W., Kremer J.P., Kenney J., et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85 5 (1995) 1341-1347
127. Faulkner L., Cooper A., Fantino C., et al. The mechanism of superantigen-mediated toxic shock: not a simple Th1 cytokine storm. J Immunol 175 10 (2005) 6870-6877
128. Sriskandan S., and Altmann D.M. The immunology of sepsis. J Pathol 214 (2008) 211-223
129. Aukrust P., Froland S.S., Liabakk N.B., et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84 7 (1994) 2136-2143
130. Wolf H.M., Hauber I., Gulle H., et al. Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc alpha R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes. Clin Exp Immunol 105 3 (1996) 537-543
131. Abe Y., Horiuchi A., Miyake M., et al. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139 (1994) 5-19
132. Arend W.P., and Leung D.Y. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 139 (1994) 71-78
133. Dinarello C.A. Is there a role for interleukin-1 blockade in intravenous immunoglobulin therapy?. Immunol Rev 139 (1994) 173-188
134. Jungi T.W., Eiholzer J., Lerch P.G., et al. The capacity of various types of immunoglobulin for intravenous use to interact with FC receptors of human monocytes and macrophages. Blut 53 4 (1986) 321-332
135. Kimberly R.P., Salmon J.E., Bussel J.B., et al. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 132 (1984) 745-750
136. Mannhalter J.W., Ahmad R., Wolf H.M., et al. Effect of polymeric IgG on human monocyte functions. Int Arch Allergy Appl Immunol 82 2 (1987) 159-167
137. Newburger J.W., Takahashi M., Burns J.C., et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315 6 (1986) 341-347
138. Newburger J.W., Takahashi M., and Beiser A.S. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324 (1991) 1633-1639
139. Newburger J.W., Sleeper L.A., McCrindle B.W., et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 356 7 (2007) 663-675
140. NIH consensus conference. Intravenous immunoglobulin: prevention and treatment of disease. JAMA 264 24 (1990) 3189-3193
141. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. N Engl J Med 325 2 (1991) 73-80
142. Spector S.A., Gelber R.D., McGrath N., et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving yidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med 331 18 (1994) 1181-1187
143. Mofenson L.M., Moye Jr. J., Korelitz J., et al. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Pediatr Infect Dis J 13 6 (1994) 477-484
144. Griffiths H., Brennan V., Lea J., et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 73 2 (1989) 366-368
145. [No authors listed]. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomised, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 319 14 (1988) 902-907
146. Chapel H.M., Lee M., Hargreaves R., et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343 8905 (1994) 1059-1063
147. van Doorn P.A., Brand A., Strengers P.F., et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled study. Neurology 40 2 (1990) 209-212
148. Vermeulen M., van Doorn P.A., and Brand A. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56 1 (1993) 36-39
149. van der Meché F.G., and Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 326 17 (1992) 1123-1129
150. Sweet L.K., Howell J., McMurray L.G., et al. The use of normal serum gamma globulin antibodies (human) concentrated (immune serum globulin) in the treatment of premature infants. J Pediatr 28 (1946) 571-573
151. Fanaroff A.A., Korones S.B., Wright L.L., et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research. N Engl J Med 330 (1994) 1107-1113
152. Sandberg K., Fasth A., Berger A., et al. Pretern infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G. J Pediatr 137 (2000) 623-628
153. Ohlsson A., and Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev (2004) CD001239
154. van der Meché F.G., and van Doorn P.A. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve 20 2 (1997) 136-147
155. Dalakas M.C. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51 6 Suppl 5 (1998) S37-S45
156. Gold R., Stangel M., and Dalakas M.C. Drug insight: the use of intravenous immunoglobulin in neurology: therapeutic considerations and practical issues. Nat Clin Pract Neurol 3 1 (2007) 36-44
157. Ratko T.A., Burnett D.A., Foulke G.E., et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 273 23 (1995) 1865-1870
158. Sacher R.A., and Ivig Advisory Panel. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 108 4 Suppl (2001) S139-S146
159. Darabi K., Abdel-Wahab O., and Dzik W.H. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 46 5 (2006) 741-753
160. Sorensen R. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. J Manag Care Pharm 13 3 (2007) 278-283
161. Ochs H.D., Fischer S.H., Wedgwood R.J., et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 76 3A (1984) 78-82
162. Roifman C.M., and Gelfand E.W. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J 7 5 Suppl (1988) S92-S96
163. Gelfand E.W., Reid B., and Roifman C.M. Intravenous immune serum globulin replacement in hypogammagloublinemia: a comparison of high- versus low-dose therapy. Monogr Allergy 23 (1988) 177-186
164. Van T., Sussman G., and Pruzanski W. Impact of intravenous infusion of low and high doses of gamma globulins (IVIG) on phagocytic functions in adults with primary humoral immunodeficiency. Inflammation 18 4 (1994) 419-426
165. Skull S., and Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child 74 6 (1996) 527-530
166. Liese J.G., Wintergerst U., Tympner K.D., et al. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 146 (1992) 335-339
167. Roifman C.M., Levison H., and Gelfand E.W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinemia and chronic lung disease. Lancet 1 8541 (1987) 1075-1077
168. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., et al. The effects of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med 135 (2001) 165-174
169. Buckley R.H. Long term use of intravenous immune globulin in patients weight primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem. J Clin Immunol 2 Suppl (1982) S15-S21
170. Bernatowska E., Madalinski K., Janowicz W., et al. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol 43 (1987) 153-162
171. de Gracia J., Vendrell M., Alvarez A., et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 47 (2004) 745-753
172. Roifman C.M., Schroeder H., Berger M., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 3 9 (2003) 1325-1333
173. Dwyer J.M., and Erlendsson K. Intraventricular gamma-globulin for the management of enterovirus encephalitis. Pediatr Infect Dis J 7 (1988) 530-533
174. Mease P.J., Ochs H.D., and Wedgwood R.J. Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in patient with X-linked agammaglobulinemia. N Engl J Med 304 (1981) 1278-1281
175. Mease P.J., Ochs H.D., Corey L., et al. Echovirus encephalitis/myositis in X-linked agammaglobulinemia. N Engl J Med 313 (1985) 758
176. Quartier P., Foray S., Casanova J.L., et al. Enteroviral meningoencephalitis in X-linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain reaction. Pediatr Infect Dis J 19 (2000) 1106-1108
177. Part 3. Adverse reactions to immunoglobulins: methods used to produce "safe" immunoglobulin preparations. In: Alving B.M., and Finlayson J.S. (Eds). Immunoglobulins: characteristics and uses of intravenous preparations. Proceedings of a workshop, DHHS Publication no. (FDA)-80-9005 (1979), Washington DC: US Department of Health and Human Services 137-225
178. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia: a review. Am J Med 76 Suppl 3a (1984) 53-60
179. Gislason D., Hanson L.A., Kjellman H., et al. Intravenous gamma-globulin infusions in patients with hypogammaglobulinemia. Vox Sang 34 (1978) 143-148
180. Cunningham-Rundles C., Day N.K., Wahn V., et al. Reactions to intravenous gammaglobulin infusions and immune complex formation. In: Nydegger U.E. (Ed). Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy (1981), Academic Press, London, New York 447-450
181. Barandun S., and Morell A. Adverse reactions to immunoglobulin preparations. In: Nydegger U.E. (Ed). Immunochemotherapy: a guide to immunoglobulin prophylaxis and therapy (1981), Academic Press, London, New York 223-227
182. Pierce L.R., and Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17 (2003) 241-251
183. Wolberg A.S., Kon R.H., Monroe D.M., et al. Coagulation factor XI is a contaminant on intravenous immunoglobulin preparations. Am J Hematol 65 1 (2000) 30-34
184. Lederman H.M., Roifman C.M., and Lavi S. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med 81 (1986) 443-446
185. Aronson D.L., and Finlayson J.S. Historical and future therapeutic plasma derivatives (epilogue). Semin Thromb Hemost VI (1980) 121-139
186. Eibl M. Treatment of defects of humoral immunity. In: Wedgwood R.J., Rosen F.S., and Paul N.W. (Eds). Primary immunodeficiency diseases. Birth defects (1983), Alan R. Liss, New York 193-200
187. Goodwin J.S., and Webb D.R. Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol 15 (1980) 106-122
188. Passwell J.H., Dayer J.M., and Merler E. Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol 123 (1979) 115-120
189. Camussi G., Aglietta M., Coda R., et al. Release of platelet activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophila and basophils. Immunol 42 (1981) 191-199
190. Eibl M.M. PKA contamination of immunoglobulin G. [letter]. N Engl J Med 313 (1985) 581
191. Alving B.M., Hojima Y., Pisano J.J., et al. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med 299 2 (1978) 66-70
192. Rosenfeld E.A., Shulman S.T., Corydon K.E., et al. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J Pediatr 126 (1995) 1000-1003
193. Schiff R.I. Transmission of viral infections through intravenous immune globulin. N Engl J Med 331 (1994) 1649-1650
194. Eibl M.M. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci 24 (2003) S222-S226
195. Miller J.L.C., Petteway Jr. S.R., and Lee D.C. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. J Allergy Clin Immunol 108 4 (2001) 91-94
196. Klaesson S., Ringdén O., Ljungman P., et al. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?. Transplantation 60 11 (1995) 1225-1230
197. Dalakas M.C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44 2 (1994) 223-226
198. Grillo J.A., Gorson K.C., Ropper A.H., et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 57 (2001) 1699-1701
199. Stangel M., Müller M., and Marx P. Adverse events during treatment with high-dose intravenous immunoglobulins for neurological disorders. Eur Neurol 40 (1998) 173-174
200. Alving B.M., Tankersley D.L., Mason B.L., et al. Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties. J Lab Clin Med 96 2 (1980) 334-346
201. Orbach H., Katz U., Sherer Y., et al. Intravenous immunoglobulins: adverse effects and safe administration. Clin Rev Allergy Immunol 29 3 (2005) 173-184
202. Kallenberg C.G. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Clin Exp Immunol 150 3 (2007) 437-441
203. Brannagan III T.H., Nagle K.J., Lange D.J., et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47 (1996) 674-677
204. Gaines A., Varricchio F., Kapit R., et al. Renal insufficiency and failure associated with globulin intravenous therapy. MMWR Morb Mortal Weekly Rep 48 (1999) 518-521
205. Stewart R.R., Winney R.J., and Cash J.D. Renal toxicity of intravenous immunoglobulin. Vox Sang 65 3 (1993) 244
206. Orbach H., Tishler M., and Shoenfeld Y. Intravenous immunoglobulin and the kidney: a two-edged sword. Semin Arthritis Rheum 34 3 (2004) 593-601
207. Cunningham-Rundles C., Zhou Z., Mankaroius S., et al. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 13 4 (1993) 272-278
208. Salama A., Schwind P., Schönhage K., et al. Rapid detection of antibodies to immunoglobulin A molecules by using the particle gel immunoassay. Vox Sang 81 1 (2002) 84-85
209. Horn J., Thon V., Bartonkova D., et al. Anti-IgA antibodies in common variable immunodeficieny (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 122 (2007) 156-162
210. Salama A., Temmesfeld B., Hippenstiel S., et al. A new strategy for the prevention of IgA anaphylactic transfusion reactions. Transfusion 44 4 (2004) 509-511
211. Burks A.W., Sampson H.A., and Buckley R.H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia: detection of IgE antibodies to IgA. N Engl J Med 314 9 (1986) 560-564
212. Chapel H.M., Spickett G.P., Ericson D., et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20 2 (2000) 94-100
213. Wade N. Hybridomas: the making of a revolution. Science 215 4536 (1982) 1073-1075
214. Baudino L., Nimmerjahn F., Azeredo da Silveira S., et al. Differential contribution of three activation IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2B-induced autoimmune hemolytic anemia in mice. J Immunol 180 3 (2008) 1948-1953
215. Nimmerjahn F., and Ravetch J.V. Fc-receptors as regulators of immunity. Adv Immunol 96 (2007) 179-204
216. Anthony R.M., Nimmerjahn F., Ashline D.J., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 5874 (2008) 373-376
217. Nimmerjahn F., and Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204 1 (2007) 11-15